Concepedia

Tobias B. Beigl

TB

5

Publications

127

Citations

5

H-Index

2020

Active since

Affiliations

University of Stuttgart(Current)

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology

Robert Bosch Hospital

Charité - Universitätsmedizin Berlin

University of Bergen

Tobias B. Beigl is an author at University of Stuttgart specializing in cancer research, cell signaling, and tumor biology.

ORCID

Top concepts

Publications per year

2020–2024

5

Publications

5

Efficient and crucial quality control of HAP1 cell ploidy status

Tobias B. Beigl, Ine Kjosås, Emilie Seljeseth et al. · Biology Open · 2020 · 42 citations · Full text

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

Sandra Weller, Astrid Toennießen, Benjamin Schaefer et al. · Cell Death Discovery · 2022 · 29 citations · Full text

, , +19

Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids

Daniela Stöhr, Jens O. Schmid, Tobias B. Beigl et al. · Cell Death and Differentiation · 2020 · 27 citations · Full text

N-terminal acetylation of actin by NAA80 is essential for structural integrity of the Golgi apparatus

Tobias B. Beigl, Monica Hellesvik, Jaakko Saraste et al. · Experimental Cell Research · 2020 · 16 citations · Full text

BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains

Tobias B. Beigl, Alexander Paul, Thomas Fellmeth et al. · EMBO Reports · 2024 · 13 citations · Full text

Rows per page

1–5 of 5